Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8858822 | 0.98 | LMNA (0.44) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL9540931 | 0.98 | LMNA (0.44) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL10765606 | 0.95 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| Ammonia Solution, Strong SCHEMBL9515772 | 0.95 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL9544281 | 0.95 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL5200301 | 0.95 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| Potassium Ion SCHEMBL9296986 | 0.95 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| Water SCHEMBL21046213 | 0.95 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| Ammonia Solution, Strong SCHEMBL21495185 | 0.95 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| Zinc Ion SCHEMBL7745848 | 0.95 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6258795-B1 | Acylated uridine and cytidine and uses thereof | PRO-NEURON, INC. | 2001-07-10 | — | — | US | disclosed |
| US-5470838-A | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine | PRO-NEURON, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0407543-A4 | MAMMALIAN GAP-43 COMPOSITIONS AND METHODS OF USE | — | 1992-10-14 | — | — | EP | disclosed |
| EP-0445229-A4 | ADHESION OF MYCOPLASMA PNEUMONIAE AND MYCOPLASMA HOMINUS TO SULFATIDE | US HEALTH (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0407543-A1 | MAMMALIAN GAP-43 COMPOSITIONS AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 1991-01-16 | — | — | EP | disclosed |
| EP-0339075-A4 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF. | PRO NEURON INC (US) | 1990-04-10 | — | — | EP | disclosed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989003837-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | disclosed |
| EP-0308452-A1 | AN ORAL COMPOSITION CONTAINING PARTICLES COMPRISING AN ACTIVE SUBSTANCE | BENZON PHARMA A/S (DK) | 1989-03-29 | — | — | EP | disclosed |
| WO-1988006893-A1 | AN ORAL COMPOSITION CONTAINING PARTICLES COMPRISING AN ACTIVE SUBSTANCE | BENZON PHARMA A/S (DK) | 1988-09-22 | — | — | WO | disclosed |